𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Seizure frequency and CSF parameters in a double-blind placebo controlled trial of gabapentin in patients with intractable complex partial seizures

✍ Scribed by Elinor Flen-Menachem; Birgitta Söderfelt; Anders Hamberger; Tomas Hedner; Lennart I. Persson


Publisher
Elsevier Science
Year
1995
Tongue
English
Weight
388 KB
Volume
21
Category
Article
ISSN
0920-1211

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


A randomised double-blind placebo-contro
✍ P. Loiseau; A.W.C. Yuen; B. Duché; T. Ménager; M.C. Arné-Bès 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 874 KB

Efficacy and safety of lamotrigine (LTG) as add-on therapy was assessed in a randomised double-blind placebo-controlled trial of this drug in 23 adult patients with refractory partial seizures. Fifteen patients showed an improvement on LTG treatment, with a greater than 50% decrease in total seizure

Gabapentin in patients with the pruritus
✍ Nora V. Bergasa; Monnie McGee; Iona H. Ginsburg; Danielle Engler 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 420 KB 👁 2 views

Pruritus is defined as the second order of nociception, the first being pain; thus, there is a rationale to study gabapentin, a drug that increases the threshold to experience nociception. The aim of this double-blind, randomized, placebo-controlled trial was to study the effect of gabapentin on the

Selected CSF biochemistry and gabapentin
✍ Elinor Ben-Menachem; Lennart I. Persson; Thomas Hedner 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 363 KB

Gabapentin (GBP) is a neutral amino acid and a GABA analog which in animal experimental models has shown a broad anticonvulsant spectrum. To evaluate the penetration of GBP into the CSF in humans as well as its possible effects on free and total GABA, homovanillic acid (HVA), and 5-hydroxyindoleacet

A double-blind, placebo-controlled evalu
✍ T Rentmeester; A Janssen; J Hulsman; F Scholtes; B van der Kleij; J Overweg; J M 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 655 KB

Sixty-two patients with uncontrolled partial seizures participated in a 12-week, double-blind, placebo-controlled add-on-trial. Thirty-two patients received loreclezole and 30 a placebo as add-on therapy. Loreclezole was targeted at a plasma level of 1-2 mg/l. In spite of an antiepileptic therapy, u